Advanced Search

Journal of Traditional Chinese Medicine >

2024 , Vol. 44 >Issue 6: 1254 - 1267

DOI: https://doi.org/10.19852/j.cnki.jtcm.20240806.005

Research Articles

Clinical efficacy and safety evaluation of Buzhongyiqi pills (补中益气丸) on appetite improvement in patients with colorectal cancer receiving chemotherapy: a pilot randomized cross-over clinical trial

  • Jianan QIAN ,
  • Yan XU ,
  • Hongyi HU ,
  • Aiguang ZHAO
Expand
  • 1 Department of Gastroenterology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China
    2 Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
    3 Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
    4 Department of Gastroenterology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

Received date: 2023-05-02

  Accepted date: 2023-09-02

  Online published: 2024-08-06

Supported by

Shanghai Municipal Administrator of Traditional Chinese Medicine-funded Project: Ding’s Clinical Medicine Huang Wendong Base Li Dongyuan "Yin Fire" Theory Inheritance and Innovation Team(2021LPTD-009)

Fold

Abstract

OBJECTIVE: To evaluate the clinical efficacy and safety of Buzhongyiqi pills (BZYQP, 补中益气丸) in improving the appetite of patients with colorectal cancer (CRC) receiving chemotherapy.

TRIAL DESIGN: A pilot, randomized, single-blind cross-over clinical trial was conducted on diagnosed stage II-IV CRC patients receiving chemotherapy.

METHODS: Patients were randomly assigned to either the BZYQP-placebo or placebo-BZYQP groups. The BZYQP-placebo group received BZYQP for 1-2 d before the first cycle of chemotherapy and continued until the end of the third cycle. A 7-day washout followed, after which they received a placebo until the end of the sixth cycle. The placebo-BZYQP group followed the opposite treatment order. The oral dose of BZYQP and placebo was ten pills three times daily. A total of 12 visit points were scheduled in this study, with each visit point carried out before and after each of the six cycles of chemotherapy. The Simplified Nutrition Appetite Questionnaire (SNAQ), the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, version 3.0), and the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, V5.0) were used to evaluate patient appetite, quality of life, and drug safety.

RESULTS: Totally 62 patients completed the study, and baseline characteristics were balanced between the BZYQP-placebo and placebo-BZYQP groups. The primary outcome, as assessed by SNAQ scores, demonstrates a statistically significant difference between the two groups during the first three cycles of chemotherapy, with the mean SNAQ score of the BZYQP-placebo group consistently higher than that of the placebo-BZYQP group from V1 (P < 0.001). After the washout period, the SNAQ score of the BZYQP-placebo group decreased from V7, and the difference in SNAQ scores between the two groups gradually became more significant after the intersection at V9. Secondary outcomes showed that during the first three cycles of chemotherapy, the BZYQP-placebo group had significantly lower scores in physical, role, emotional, cognitive, and social functioning domains, as well as in fatigue, loss of appetite, and diarrhea symptoms, compared to the placebo-BZYQP group (P < 0.001). Scores for physical, role, emotional, cognitive, and social functioning in the BZYQP-placebo group remained lower (P < 0.05) at V11. The chemotherapy-induced adverse events (AEs) in the BZYQP-placebo group were significantly lower than those in the placebo-BZYQP group at V5, mainly in nausea and vomiting (9.1% vs 62.1%, P < 0.001), diarrhea (12.1% vs 44.8%, P = 0.004), and anemia (15.2% vs 41.4%, P = 0.021). No drug-related events were reported in this study.

CONCLUSION: BZYQP is feasible and safe to effectively improve the appetite of patients with CRC receiving chemotherapy and help them with better quality of life.

Key words： colorectal neoplasms; appetite; quality of life; adverse events; pilots; cross-over studies; randomized controlled trials; Buzhongyiqi pills

Cite this article

Jianan QIAN , Yan XU , Hongyi HU , Aiguang ZHAO . Clinical efficacy and safety evaluation of Buzhongyiqi pills (补中益气丸) on appetite improvement in patients with colorectal cancer receiving chemotherapy: a pilot randomized cross-over clinical trial[J]. Journal of Traditional Chinese Medicine, 2024 , 44(6) : 1254 -1267 . DOI: 10.19852/j.cnki.jtcm.20240806.005

References

1. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin 2023; 73: 233-54.
2. Qian JN, Bao CQ, Hu HY. Research progress of Traditional Chinese Medicine in treatment of gastrointestinal adverse effects of colon cancers caused by chemotherapy. Zhong Guo Zhong Xi Yi Jie He Xiao Hua Za Zhi 2022; 30: 456-60.
3. Davis MP, Dreicer R, Walsh D, Lagman R, LeGrand SB. Appetite and cancer-associated anorexia: a review. J Clin Oncol 2004; 22: 1510-7.
4. Hariyanto TI, Kurniawan A. Appetite problem in cancer patients: pathophysiology, diagnosis, and treatment. Cancer Treat Res Commun 2021; 27: 100336.
5. Shinsyu A, Bamba S, Kurihara M, et al. Inflammatory cytokines, appetite?regulating hormones, and energy metabolism in patients with gastrointestinal cancer. Oncol Lett 2020; 20: 1469-79.
6. Meng QY, Tan SJ, Jiang Y, et al. Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: a randomized clinical trial. Clin Nutr 2021; 40: 40-6.
7. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372: 621-30.
8. Gupta A, Nshuti L, Grewal US, et al. Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS). J Clin Oncol 2021; 39: 55.
9. Arora N, Ramesh V, Virnig BA, Blaes AH, Gupta A. Medications to manage cancer-associated anorexia/cachexia syndrome (CACS) in patients with advanced gastrointestinal (GI) cancer. J Clin Oncol 2022; 40: 658.
10. Naito T, Uchino J, Kojima T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. Cancer 2022; 128: 2025-35.
11. Zarifi SH, Bagherniya M, Banach M, Johnston TP, Sahebkar A. Phytochemicals: a potential therapeutic intervention for the prevention and treatment of cachexia. Clin Nutr 2022; 41: 2843-57.
12. Ruiz-García V, López-Briz E, Carbonell-Sanchis R, Bort-Martí S, Gonzálvez-Perales JL. Megestrol acetate for cachexia-anorexia syndrome. A systematic review. J Cachexia Sarcopenia Muscle 2018; 9: 444-52.
13. Li J, Yang HY. Clinical observation of Buzhong Yiqi pill in the treatment of breast-cancer-related fatigue. Liaoning Yi Xue Yuan Xue Bao 2015; 36: 12-4.
14. Ke W. A study of Buzhong Yiqi decoction combined with CapeOX chemotherapy for the treatment of advanced gastric cancer. Ji Ceng Yi Xue Lun Tan 2022; 26: 67-9.
15. Costa RGF, Caro PL, De Matos-Neto EM, et al. Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa. J Cachexia Sarcopenia Muscle 2019; 10: 1116-27.
16. Wilson M-MG, Thomas DR, Rubenstein LZ, et al. Appetite assessment: Simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr 2005; 82: 1074-81.
17. Sun LY, Mao JJ, Liu Q, Yang YF, He B. Effects of auricular acupuncture on appetite in patients with advanced cancer: a pilot randomized controlled trial. Ann Palliat Med 2020; 9: 1804-11.
18. Koh SJ, Oh SY, Baek JY, et al. Validity and reliability of Korean version of simplified nutritional appetite questionnaire in patients with advanced cancer: a multicenter, longitudinal study. J Clin Oncol 2017; 35: 211.
19. El Alami Y, Essangri H, Majbar MA, et al. Psychometric validation of the Moroccan version of the EORTC QLQ-C 30 in colorectal cancer patients: cross-sectional study and systematic literature review. BMC Cancer 2021; 21: 99.
20. Wan CH, Chen MQ, Zhang CZ, Tang XL, Meng Q, Zhang XQ. The Chinese version of EORTC QLQ-C3 form in evaluation of quality of life for patients with cancer. Shi Yong Zhong Liu Za Zhi 2005; 20: 353-5.
21. Kruizenga HM, Seidell JA, De Vet HCW, Van Bokhorst MAE. Development of a short nutritional assessment questionnaire (SNAQ). Clin Nutr 2003; 22: S96.
22. Ouyang MZ, Liu YY, Tan W, et al. Bu-Zhong-Yi-Qi pill alleviate the chemotherapy-related fatigue in 4 T 1 murine breast cancer model. BMC Complement Altern Med 2014; 14: 497.
23. Inoue M, Hoshino E. Symptoms of cancer patients and kampo formulas effective for them. Gan Kagaku Ryoho 2015; 42: 2418-22.
24. He M, Chen WW, Wang MM, et al. Simultaneous determination of multiple bioactive components of Bu-Zhong-Yi-Qi-Tang in rat tissues by LC-MS/MS: application to a tissue distribution study. J Chromatogr B 2017; 1044-1045: 177-84.
25. Liu K, Wang BJ, Ma H, Song XL, Bian RQ. Influences of Buzhong Yiqi tang on gastrointestinal function and nutriture status of gastric carcinoma after operation. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2015; 21: 152-6.
26. Liu XL, Wang RJ, Fu QS. Effect of Buzhongyiqi decoction on MEK/ERKmRNA expression in gastric mucosa of rats with spleen deficiency. Zhong Yao Yao Li Yu Lin Chuang 2013; 29: 5-8.
27. Xiong Y, Shang BZ, Xu SY, Zhao R, Gou H, Wang C. Protective effect of Bu-zhong-yi-qi decoction, the water extract of Chinese traditional herbal medicine, on 5-fluorouracil-induced renal injury in mice. Ren Fail 2016; 38: 1240-8.
28. Kim J, Kim H, Kim KH. Effects of Bu-Zhong-Yi-Qi-Tang for the treatment of functional dyspepsia: a feasibility study protocol. Integr Med Res 2017; 6: 317-24.
29. Hu LF, Yao ZH, Qin ZF, et al. In vivo metabolic profiles of Bu-Zhong-Yi-Qi-Tang, a famous Traditional Chinese Medicine prescription, in rats by ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. J Pharm Biomed Anal 2019; 171: 81-98.
30. Cai MD, Yang EJ. Hochu-Ekki-To improves motor function in an amyotrophic lateral sclerosis animal model. Nutrients 2019; 11: 2644.
31. Yakabe M, Hosoi T, Sasakawa H, Akishita M, Ogawa S. Kampo formula Hochu-Ekki-To (Bu-Zhong-Yi-Qi-Tang, TJ-41) ameliorates muscle atrophy by modulating atrogenes and AMPK in vivo and in vitro. BMC Complement Med Ther 2022; 22: 341.
32. Ahmadimoghaddam D, Zarei M, Mohammadi S, Izadidastenaei Z, Salehi I. Bupleurum falcatum L. alleviates nociceptive and neuropathic pain: potential mechanisms of action. J Ethnopharmacol 2021; 273: 113990.
33. Kim SM, Kim SC, Chung IK, Cheon WH, Ku SK. Antioxidant and protective effects of Bupleurum Falcatum on the L-thyroxine-induced hyperthyroidism in rats. Evid Based Complement Alternat Med 2012; 2012: 578497.
34. Lee MY, Shin IS, Jeon WY, et al. Protective effect of Bojungikki-tang, a traditional herbal formula, against alcohol-induced gastric injury in rats. J Ethnopharmacol 2012; 142: 346-53.
35. Li XM, Wang XL, Han CY, et al. Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway. Free Radic Biol Med 2013; 60: 168-76.
36. Grabiec K, Burchert M, Milewska M, B?aszczyk M, Grzelkowska-Kowalczyk K. Systemic and local mechanisms leading to cachexia in cancer. Adv Hyg Exp Med 2013; 67: 1397-409.
37. Shu G, Xu D, Ran CL, et al. Protective effect of dietary supplementation of Bupleurum falcatum L Saikosaponins on ammonia exposure-induced ileum injury in broilers. Poult Sci 2021; 100: 100803.
38. Li XJY, Li XY, Huang NN, Liu RP, Sun R. A comprehensive review and perspectives on pharmacology and toxicology of Saikosaponins. Phytomedicine 2018; 50: 73-87.
39. Han H, Yi B, Zhong RQ, et al. From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators. Microbiome 2021; 9: 162.
40. Utsuyama M, Seidlar H, Kitagawa M, Hirokawa K. Immunological restoration and anti-tumor effect by Japanese herbal medicine in aged mice. Mech Ageing Dev 2001; 122: 341-52.
41. Ishimitsu R, Nishimura H, Kawauchi H, Kawakita T, Yoshikai Y. Dichotomous effect of a traditional Japanese medicine, Bu-Zhong-Yi-Qi-Tang on allergic asthma in mice. Int Immunopharmacol 2001; 1: 857-65.
42. Yamaoka Y, Kawakita T, Nomoto K. Protective effect of a traditional Japanese medicine Hochu-Ekki-To (Chinese name: Bu-Zhong-Yi-Qi-Tang), on the susceptibility against Listeria monocytogenes in infant mice. Int Immunopharmacol 2001; 1: 1669-77.
43. Liu LY, Hu LF, Yao ZH, et al. Mucosal immunomodulatory evaluation and chemical profile elucidation of a classical traditional Chinese formula, Bu-Zhong-Yi-Qi-Tang. J Ethnopharmacol 2019; 228: 188-99.
44. Gemta LF, Siska PJ, Nelson ME, et al. Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells. Sci Immunol 2019; 4: eaap9520.
45. Tsuge A, Chiba SSK, Yagura Y, et al. Hochuekkito exerts the anti-allergic effects via activating regulatory T cells in a murine model of contact hypersensitivity. J Nat Med 2023; 77: 352-62.
46. Kuroiwa A, Liou S, Yan H, Eshita A, Naitoh S, Nagayama A. Effect of a traditional Japanese herbal medicine, Hochu-ekki-to (Bu-Zhong-Yi-Qi Tang), on immunity in elderly persons. Int Immunopharmacol 2004; 4: 317-24.
47. Minagawa T, Domen T, Suzuki T, et al. Effectiveness of hochuekkito (Japanese herbal medicine) for general fatigue after introduction of enzalutamide in three cases of castration-resistant prostate cancer. Jpn J Urol 2019; 110: 86-91.
48. Okabe H, Kinjo Y, Obama KZTK, et al. A randomized phaseⅡ study of S-1 adjuvant chemotherapy with or without Hochu-Ekki-To, a Japanese herbal medicine, for stage Ⅱ/Ⅲ gastric cancer: The KUGC07 (SHOT) trial. Front Oncol 2019; 9: 294.
49. Nagata N. Current status of Japanese traditional medicine “Kampo” in chemotherapy. Gan Kagaku Ryoho 2015; 42: 2423-9.
Options
Outlines

/

〈 〉